Svenja Fischmann

Detection of the recently emerged synthetic cannabinoid 4F‐MDMB‐BINACA in “legal high” products and human urine specimens

Belal Haschimi, Lukas Mogler, Sebastian Halter et al. · Drug Testing and Analysis · 2019 · 54 citations

Pharmacy, Pharmacology, Toxicology +16

How to Study the Metabolism of New Psychoactive Substances for the Purpose of Toxicological Screenings—A Follow-Up Study Comparing Pooled Human Liver S9, HepaRG Cells, and Zebrafish Larvae

Lea Wagmann, Fabian Frankenfeld, Yu Mi Park et al. · Frontiers in Chemistry · 2020 · 53 citations · Full text

Pharmacy, Biochemistry, Toxicology +17

Comparison of Three Untargeted Data Processing Workflows for Evaluating LC-HRMS Metabolomics Data

Selina Hemmer, Sascha K. Manier, Svenja Fischmann et al. · Metabolites · 2020 · 38 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

EMCDDA framework and practical guidance for naming synthetic cannabinoids

Benedikt Pulver, Svenja Fischmann, Ana Gallegos et al. · Drug Testing and Analysis · 2022 · 37 citations

Medicine, Pharmacology, Clinical Pharmacology +12

Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4´-fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine

Tanja M. Gampfer, Lea Wagmann, Yu Mi Park et al. · Archives of Toxicology · 2020 · 34 citations · Full text

Pharmacy, Pharmacology, Toxicology +17